Cargando…
Therapeutic trial in hereditary angioedema type III: Icatibant
Autores principales: | Garro, Laila Sabino, Porter, Maria Helena Mattos, Komaroff, Fernanda, Adachi, Caroline Terumi, Malheiros, Maria Teresinha, Mello, Yara, Ribeiro, Marisa Rosimeire |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407049/ http://dx.doi.org/10.1186/1939-4551-8-S1-A220 |
Ejemplares similares
-
Occupational contact dermatitis due to captopril
por: Ribeiro, Marisa Rosimeire, et al.
Publicado: (2015) -
Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study
por: Campos, Regis Albuquerque, et al.
Publicado: (2014) -
Hereditary angioedema: epidemiology, management, and role of icatibant
por: Ghazi, Aasia, et al.
Publicado: (2013) -
Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010) -
Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema
por: Farkas, Henriette, et al.
Publicado: (2021)